Nothing Special   »   [go: up one dir, main page]

ATA172889A - Furanderivate - Google Patents

Furanderivate

Info

Publication number
ATA172889A
ATA172889A AT0172889A AT172889A ATA172889A AT A172889 A ATA172889 A AT A172889A AT 0172889 A AT0172889 A AT 0172889A AT 172889 A AT172889 A AT 172889A AT A172889 A ATA172889 A AT A172889A
Authority
AT
Austria
Prior art keywords
furanderivate
Prior art date
Application number
AT0172889A
Other languages
English (en)
Other versions
AT398200B (de
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888817098A external-priority patent/GB8817098D0/en
Priority claimed from GB898904686A external-priority patent/GB8904686D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ATA172889A publication Critical patent/ATA172889A/de
Application granted granted Critical
Publication of AT398200B publication Critical patent/AT398200B/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT0172889A 1988-07-18 1989-07-17 Furanderivate AT398200B (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888817098A GB8817098D0 (en) 1988-07-18 1988-07-18 Chemical compounds
GB898904686A GB8904686D0 (en) 1989-03-01 1989-03-01 Chemical compounds

Publications (2)

Publication Number Publication Date
ATA172889A true ATA172889A (de) 1994-02-15
AT398200B AT398200B (de) 1994-10-25

Family

ID=26294175

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0172889A AT398200B (de) 1988-07-18 1989-07-17 Furanderivate

Country Status (35)

Country Link
US (1) US5008256A (de)
JP (1) JP2523185B2 (de)
KR (1) KR0122598B1 (de)
CN (1) CN1022626C (de)
AT (1) AT398200B (de)
AU (1) AU632052B2 (de)
BE (1) BE1003254A5 (de)
CA (1) CA1332610C (de)
CH (1) CH679582A5 (de)
CY (1) CY1650A (de)
DE (1) DE3923638C2 (de)
DK (1) DK168381B1 (de)
EG (1) EG19368A (de)
ES (1) ES2014175A6 (de)
FI (1) FI90538C (de)
FR (1) FR2634122B1 (de)
GB (1) GB2220937B (de)
GR (1) GR1000431B (de)
HK (1) HK61392A (de)
HU (2) HU206104B (de)
IE (1) IE61076B1 (de)
IL (1) IL91005A (de)
IT (1) IT1231481B (de)
LU (2) LU88722I2 (de)
MX (1) MX174145B (de)
MY (1) MY104055A (de)
NL (2) NL192604C (de)
NO (2) NO176319C (de)
NZ (1) NZ229958A (de)
PL (1) PL162391B1 (de)
PT (1) PT91188B (de)
SE (1) SE468715B (de)
SG (1) SG51992G (de)
YU (1) YU47021B (de)
ZW (1) ZW8689A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282132B1 (de) * 1987-03-09 1992-09-30 The Procter & Gamble Company Zusammensetzungen und ihre Verwendung zur Behandlung von Magen-Darmstörungen
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
AU641903B2 (en) * 1988-10-26 1993-10-07 Glaxo Group Limited Carboxylic acid derivatives
GB9004328D0 (en) * 1990-02-27 1990-04-25 Glaxo Group Ltd Chemical compounds
GB9009240D0 (en) * 1990-04-25 1990-06-20 Glaxo Group Ltd Chemical compounds
GB9009437D0 (en) * 1990-04-26 1990-06-20 Glaxo Group Ltd Chemical compounds
DK0540613T3 (da) * 1990-07-20 1996-04-01 Tillotts Pharma Ag Produkter og fremgangsmåder til behandling af fordøjelseskanalen
GB9019875D0 (en) * 1990-09-11 1990-10-24 Glaxo Group Ltd Pharmaceutical compositions
US5192752A (en) * 1991-01-14 1993-03-09 The Procter & Gamble Company Swallowable pharmaceutical compositions containing colloidal bismuth subcitrate
US5128140A (en) * 1991-01-14 1992-07-07 The Procter & Gamble Company Swallowable pharmaceutical compositions
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
ES2130152T3 (es) * 1991-12-06 1999-07-01 Glaxo Group Ltd Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.
AU1671295A (en) * 1994-12-19 1996-07-10 Lauteral Limited Combinations of ranitidine hydrochloride-form 1 and bismuth compounds
GB9501560D0 (en) 1995-01-26 1995-03-15 Nycomed Imaging As Contrast agents
EP0805815B1 (de) * 1995-01-26 2002-04-10 Nycomed Imaging A/S Verwendung von WISMUTVERBINDUNGEN zur Herstellung eines Arzneimittels zur Behandlung von Magenverstimmungen, die durch Helicobacter pylori verursacht werden
EP1035192A1 (de) * 1999-01-26 2000-09-13 Stefan Graichen Additiv für einen Kühlschmierstoff
CN1102585C (zh) * 1999-04-28 2003-03-05 常州兰陵制药有限公司 雷尼替丁枸橼酸铋盐的制备方法
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
CN100402514C (zh) * 2006-08-01 2008-07-16 丽珠医药集团股份有限公司 一种制备枸橼酸铋雷尼替丁的方法
CN101484132A (zh) * 2007-07-09 2009-07-15 柏树制药公司 具有合意口味的雷尼替丁制剂
CN102408398B (zh) * 2011-09-20 2012-12-05 江苏汉斯通药业有限公司 枸橼酸铋雷尼替丁的制备方法
US9731999B2 (en) 2011-09-23 2017-08-15 Iqbal Gill Chemical admixtures for hydraulic cements
ES2426539B1 (es) * 2012-04-18 2014-09-09 Dr Healthcare España, S. L. Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd)
CN103896888B (zh) * 2014-03-28 2015-11-18 常州兰陵制药有限公司 枸橼酸铋雷尼替丁的制备方法
WO2015155297A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of dabigatran and h2-receptor antagonists
EP2942058A1 (de) 2014-05-09 2015-11-11 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmazeutische Kombinationen aus Rivaroxaban und Histamin-H2-Rezeptorantagonisten
CN107382921A (zh) * 2017-07-28 2017-11-24 常州兰陵制药有限公司 制备枸橼酸铋雷尼替丁的方法
WO2022034121A1 (en) 2020-08-11 2022-02-17 Université De Strasbourg H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
FR2531706A1 (fr) * 1982-08-13 1984-02-17 Sanofi Sa Benzamides, leurs sels, procede pour leur preparation et compositions pharmaceutiques les renfermant
BE905235A (fr) * 1986-08-05 1986-12-01 Hasunor Ag Ascorbates antagonistes des recepteurs h2 et leur procede de preparation.
IT1215325B (it) * 1987-01-07 1990-02-08 Barisintex Sa Composti antagonisti di recettori -h2 e procedimento per la loro preparazione.
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
EP0282132B1 (de) * 1987-03-09 1992-09-30 The Procter & Gamble Company Zusammensetzungen und ihre Verwendung zur Behandlung von Magen-Darmstörungen
DE3710462A1 (de) * 1987-03-30 1988-10-13 Heumann Pharma Gmbh & Co Pharmazeutische zubereitung zur behandlung von erkrankungen des magen-darm-traktes
GB9004328D0 (en) * 1990-02-27 1990-04-25 Glaxo Group Ltd Chemical compounds
GB9009437D0 (en) * 1990-04-26 1990-06-20 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
ES2014175A6 (es) 1990-06-16
IT8948196A0 (it) 1989-07-17
FR2634122B1 (fr) 1993-11-19
GB8916288D0 (en) 1989-08-31
AU3817889A (en) 1990-01-18
YU47021B (sh) 1994-11-15
CH679582A5 (de) 1992-03-13
FI90538B (fi) 1993-11-15
NL192604B (nl) 1997-07-01
CN1022626C (zh) 1993-11-03
MY104055A (en) 1993-10-30
CY1650A (en) 1992-12-11
ZW8689A1 (en) 1990-02-21
GR1000431B (el) 1992-07-30
DE3923638A1 (de) 1990-03-01
HK61392A (en) 1992-08-21
FI893448A (fi) 1990-01-19
NO176319B (no) 1994-12-05
NL970046I2 (nl) 1998-04-01
BE1003254A5 (fr) 1992-02-11
FI893448A0 (fi) 1989-07-17
DK351789D0 (da) 1989-07-17
DK168381B1 (da) 1994-03-21
NL192604C (nl) 1997-11-04
CN1039419A (zh) 1990-02-07
MX174145B (es) 1994-04-25
MX16829A (es) 1993-10-01
HU211173A9 (en) 1995-11-28
CA1332610C (en) 1994-10-18
NO892936D0 (no) 1989-07-17
EG19368A (en) 1995-02-28
SE468715B (sv) 1993-03-08
PL162391B1 (pl) 1993-10-30
GR890100454A (en) 1990-06-27
IE892309L (en) 1990-01-18
YU142789A (en) 1991-04-30
KR910002826A (ko) 1991-02-26
HU206104B (en) 1992-08-28
JP2523185B2 (ja) 1996-08-07
AU632052B2 (en) 1992-12-17
LU87557A1 (fr) 1990-07-24
GB2220937B (en) 1991-11-27
PT91188B (pt) 1995-03-01
SE8902550L (sv) 1990-01-19
IE61076B1 (en) 1994-09-21
US5008256A (en) 1991-04-16
NL8901840A (nl) 1990-02-16
IL91005A0 (en) 1990-02-09
IL91005A (en) 1994-10-07
NO176319C (no) 1995-03-15
FR2634122A1 (fr) 1990-01-19
IT1231481B (it) 1991-12-07
NZ229958A (en) 1991-09-25
JPH02117684A (ja) 1990-05-02
NO1998007I1 (no) 1998-02-05
GB2220937A (en) 1990-01-24
DE3923638C2 (de) 1995-11-23
NL970046I1 (nl) 1998-03-02
SE8902550D0 (sv) 1989-07-17
NO892936L (no) 1990-01-19
AT398200B (de) 1994-10-25
DK351789A (da) 1990-01-19
HUT52082A (en) 1990-06-28
PT91188A (pt) 1990-02-08
LU88722I2 (fr) 1996-08-23
KR0122598B1 (ko) 1997-11-13
FI90538C (fi) 1994-02-25
SG51992G (en) 1992-07-24

Similar Documents

Publication Publication Date Title
FI931981A0 (fi) Hopmonterbart konstruktionssystem
ATA901789A (de) Somatostatinpeptid
BR8806093A (pt) Trepano
DK233989D0 (da) Mejetaerskerskaerebord
ATA900689A (de) Calcitoninpeptide
ATA172889A (de) Furanderivate
DK188690D0 (da) Neutrocyt-aktiverende peptid-2
DK184489D0 (da) Bicyclodioner
DK201989D0 (da) Anaestesifordamper
DE68926597D1 (de) Mikrorechner
BR8902098A (pt) Eletrolisador
DK238390A (da) Flyderoersbro
DK113291D0 (da) Homogent enzymimmunassay
BR8906898A (pt) Jamela
DK137889A (da) Foldeaeske
DK182290D0 (da) Foldeaeske
DK318789D0 (da) Mitomycin-n7-alkylfosfatderivater
DK608189A (da) Camouflagenet
DE68926367D1 (de) Hydroxymethylcyclobutylpurine
DD277186A3 (de) Waelzlagerseparator
BR8806232A (pt) Bau-casa
BR6800002U (pt) Multigabarito
SE8802519D0 (sv) Sjukvardsveska
DK102689D0 (da) Renoverbar lynlaas
BR6800108U (pt) Supercross

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
SZA Application filed for a certificate of protection

Free format text: SZ 1/1996, 19960219

EZF Grant of a certificate of protection

Free format text: SZ 1/1996, 19960219, EXPIRES:20100714

ELJ Ceased due to non-payment of the annual fee